{"groups":[{"description":"Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic \\[related or unrelated\\] Hematopoietic SCT.\n\nPentostatin: 4 mg/m2/24 hour IV continuously over 72 hours on days -8 to -6. Alemtuzumab: 20 mg per dose IV over 8 hours on days -5 to -1. Patients then received infusion of related or unrelated donor peripheral blood progenitor cells on day 0. Patients also receive cyclosporine IV continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.","id":"FG000","title":"Preparative Regimen of Pentostatin and Alemtuzumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Sister withdrew as donor"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Off study pre transplant by clinic MD"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"14"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Following consent process, subjects who consented to participate were screened per the selection criteria in the study.","recruitmentDetails":"Following University of Arizona IRB review and approval, the study opened to accrual on November 2005 at the Arizona Cancer Center clinic and University Medical Center sites \\[Tucson, Arizona\\]."}